Faculty

Back to Index
Michael Frederick Press, MD, PhD
Professor of Pathology
Harold E. Lee Chair in Breast Cancer Research
Director of Breast Cancer Analysis Lab
Pathology
NOR 5411 Health Sciences Campus Los Angeles
+1 323 865 0563

Overview

Michael F. Press, M.D., Ph.D. is a professor in the Department of Pathology and co-leader of the Women’s Cancers Program. He received his M.D., Ph.D. and residency training at the University of Chicago. He was a member of the University of Chicago faculty for seven years before joining the faculty of the University of Southern California in 1988. Dr. Press is currently the director for the Breast Cancer International Research Group Central Laboratory, the coordinator of the Breast Cancer Program at USC Norris Cancer Center and holds the Harold E. Lee Chair in Cancer Research in the USC Norris Cancer Center. His research interests are molecular genetic alterations in breast and gynecologic cancers.

Publications

Press OA, Guzman R, Cervantes M, Santiago A, Press MF. Characterization of HER2 Status by Fluorescence In Situ Hybridizatign (FISH) and Imeunohistochemistry (IHC). Methods Mol Biol. 20143 1180:181-207. 'prns:informatiofResourceReference>. View in: PubMed

. View in: PubMed

. View in: PubMed

Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: a pooled analysis. Breast Cancer Res. 2017 Jan 13; 19(1):6. View in: PubMed

HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib. Mol Cancer Ther. 2017 Jan; 16(1):228-238. View in: PubMed

Genome-wide association studies in women of African ancestry identified 3q26. 21 as a novel susceptibility locus for oestrogen receptor negative breast cancer. Hum Mol Genet. 2016 Nov 01; 25(21):4835-4846. View in: PubMed

Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. JAMA Oncol. 2016 Oct 1; 2(10):1287-1294. View in: PubMed

Genetic variants in microRNA and microRNA biogenesis pathway genes and breast cancer risk among women of African ancestry. Hum Genet. 2016 Oct; 135(10):1145-59. View in: PubMed

Genome-wide association studies in women of African ancestry identified 3q26. 21 as a novel susceptibility locus for oestrogen receptor negative breast cancer. Hum Mol Genet. 2016 Sep 4. View in: PubMed

HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials. J Clin Oncol. 2016 Aug 29. View in: PubMed

Assessing the New American Society of Clinical Oncology/College of American Pathologists Guidelines for HER2 Testing by Fluorescence In Situ Hybridization: Experience of an Academic Consultation Practice. Arch Pathol Lab Med. 2016 Apr 15. View in: PubMed

Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer. J Clin Oncol. 2016 Mar 20; 34(9):936-44. View in: PubMed

Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells. Oncotarget. 2016 Feb 23; 7(8):9561-75. View in: PubMed

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC-A Randomized Phase III Trial. J Clin Oncol. 2016 Feb 10; 34(5):443-51. View in: PubMed

Many private mutations originate from the first few divisions of a human colorectal adenoma. J Pathol. 2015 Nov; 237(3):355-62. View in: PubMed

Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers. J Mol Diagn. 2015 Sep; 17(5):487-95. View in: PubMed

Reduced risk of breast cancer associated with recreational physical activity varies by HER2 status. Cancer Med. 2015 Jul; 4(7):1122-35. View in: PubMed

PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance. Clin Cancer Res. 2015 May 1; 21(9):2065-74. View in: PubMed

Reply to e. a. Rakha et Al. J Clin Oncol. 2015 Apr 10; 33(11):1302-4. View in: PubMed

A Big Bang model of human colorectal tumor growth. Nat Genet. 2015 Mar; 47(3):209-16. View in: PubMed

Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia. Clin Epigenetics. 2015; 7:117. View in: PubMed

Molecular markers for breast cancer diagnosis, prognosis and targeted therapy. J Surg Oncol. 2015 Jan; 111(1):81-90. View in: PubMed

Non-coding RNAs derived from an alternatively spliced REST transcript (REST-003) regulate breast cancer invasiveness. Sci Rep. 2015; 5:11207. View in: PubMed

Methodological Considerations in Estimation of Phenotype Heritability Using Genome-Wide SNP Data, Illustrated by an Analysis of the Heritability of Height in a Large Sample of African Ancestry Adults. PLoS One. 2015; 10(6):e0131106. View in: PubMed

A comprehensive examination of breast cancer risk loci in African American women. Hum Mol Genet. 2014 Oct 15; 23(20):5518-26. View in: PubMed

Genome-wide Scan of 29,141 African Americans Finds No Evidence of Directional Selection since Admixture. Am J Hum Genet. 2014 Oct 2; 95(4):437-44. View in: PubMed

Meta-analysis of loci associated with age at natural menopause in African-American women. Hum Mol Genet. 2014 Jun 15; 23(12):3327-42. View in: PubMed

HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics. Breast Cancer Res Treat. 2014 May; 145(1):193-203. View in: PubMed

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology/college of american pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014 Feb; 138(2):241-56. View in: PubMed

Quantitative ER and PgR Assessment as Predictors of Benefit from Lapatinib in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Clin Cancer Res. 2014 Feb 1; 20(3):736-43. View in: PubMed

Characterization of HER2 Status by Fluorescence In Situ Hybridization (FISH) and Immunohistochemistry (IHC). Methods Mol Biol. 2014; 1180:181-207. View in: PubMed

A conceptual and methodological framework for investigating etiologic heterogeneity. Stat Med. 2013 Dec 20; 32(29):5039-52. View in: PubMed

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013 Nov 1; 31(31):3997-4013. View in: PubMed

Genome-wide association study of age at menarche in African-American women. Hum Mol Genet. 2013 Aug 15; 22(16):3329-46. View in: PubMed

A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet. 2013 Jun; 45(6):690-6. View in: PubMed

Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet. 2013 Apr; 45(4):392-8, 398e1-2. View in: PubMed

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Res Treat. 2013 Feb; 138(1):99-108. View in: PubMed

Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status. BMC Cancer. 2013; 13:225. View in: PubMed

Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women. Breast Cancer Res. 2013; 15(5):R90. View in: PubMed

A genome-wide scan for breast cancer risk haplotypes among African American women. PLoS One. 2013; 8(2):e57298. View in: PubMed

A genome-wide association study of breast cancer in women of African ancestry. Hum Genet. 2013 Jan; 132(1):39-48. View in: PubMed

A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet. 2012 Dec 15; 21(24):5373-84. View in: PubMed

Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomarkers Prev. 2012 Oct; 21(10):1848-55. View in: PubMed

Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trial. Contraception. 2012 Sep; 86(3):238-43. View in: PubMed

Potential utility of an expression array signature for predicting anthracycline responsiveness or resistance. J Clin Oncol. 2012 Feb 1; 30(4):357-61. View in: PubMed

Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: Pooled results from three countries. Breast Cancer Res. 2012; 14(3):R91. View in: PubMed

Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis. BMC Cancer. 2012; 12:597. View in: PubMed

A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet. 2011 Dec; 43(12):1210-4. View in: PubMed

Fine-mapping of breast cancer susceptibility loci characterizes genetic risk in African Americans. Hum Mol Genet. 2011 Nov 15; 20(22):4491-503. View in: PubMed

Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Res Treat. 2011 Nov; 130(2):587-97. View in: PubMed

Pathological characteristics of BRCA-associated breast cancers in Hispanics. Breast Cancer Res Treat. 2011 Nov; 130(1):281-9. View in: PubMed

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol. 2011 Oct 10; 29(29):3877-84. View in: PubMed

Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011 Oct 6; 365(14):1273-83. View in: PubMed

Identification, replication, and fine-mapping of Loci associated with adult height in individuals of african ancestry. PLoS Genet. 2011 Oct; 7(10):e1002298. View in: PubMed

Obesity and survival among black women and white women 35 to 64 years of age at diagnosis with invasive breast cancer. J Clin Oncol. 2011 Sep 1; 29(25):3358-65. View in: PubMed

The landscape of recombination in African Americans. Nature. 2011 Aug 11; 476(7359):170-5. View in: PubMed

Enhanced statistical tests for GWAS in admixed populations: assessment using African Americans from CARe and a Breast Cancer Consortium. PLoS Genet. 2011 Apr; 7(4):e1001371. View in: PubMed

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol. 2011 Mar 1; 29(7):859-67. View in: PubMed

Does hormone therapy counter the beneficial effects of physical activity on breast cancer risk in postmenopausal women? Cancer Causes Control. Does hormone therapy counter the beneficial effects of physical activity on breast cancer risk in postmenopausal women? Cancer Causes Control. 2011 Mar; 22(3):515-22. View in: PubMed

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol. 2011 Jan 10; 29(2):149-56. View in: PubMed

Genome-scale screen for DNA methylation-based detection markers for ovarian cancer. PLoS One. 2011; 6(12):e28141. View in: PubMed

Fine scale mapping of the breast cancer 16q12 locus. Hum Mol Genet. 2010 Jun 15; 19(12):2507-15. View in: PubMed

A case-control study of body mass index and breast cancer risk in white and African-American women. Cancer Epidemiol Biomarkers Prev. 2010 Jun; 19(6):1532-44. View in: PubMed

Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer. Clin Cancer Res. 2010 Feb 15; 16(4):1281-8. View in: PubMed

Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study. Cancer Res. 2010 Jan 15; 70(2):575-87. View in: PubMed

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009 Nov 20; 27(33):5538-46. View in: PubMed

Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study. J Clin Oncol. 2009 Nov 20; 27(33):5552-8. View in: PubMed

An admixture scan in 1,484 African American women with breast cancer. Cancer Epidemiol Biomarkers Prev. 2009 Nov; 18(11):3110-7. View in: PubMed

Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. J Clin Oncol. 2009 Aug 20; 27(24):3908-15. View in: PubMed

Breast cancer receptor status: do results from a centralized pathology laboratory agree with SEER registry reports? Cancer Epidemiol Biomarkers Prev. Breast cancer receptor status: do results from a centralized pathology laboratory agree with SEER registry reports? Cancer Epidemiol Biomarkers Prev. 2009 Aug; 18(8):2214-20. View in: PubMed

Relationship between migraine history and breast cancer risk among premenopausal and postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2009 Jul; 18(7):2030-4. View in: PubMed

Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers. J Natl Cancer Inst. 2009 May 6; 101(9):615-8. View in: PubMed

Admixture mapping of 15,280 African Americans identifies obesity susceptibility loci on chromosomes 5 and X. PLoS Genet. 2009 May; 5(5):e1000490. View in: PubMed

FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. Hum Mol Genet. 2009 May 1; 18(9):1692-703. View in: PubMed

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009 Mar 10; 27(8):1323-33. View in: PubMed

Is there a difference in the association between percent mammographic density and subtypes of breast cancer? Luminal A and triple-negative breast cancer. Cancer Epidemiol Biomarkers Prev. 2009 Feb; 18(2):479-85. View in: PubMed

A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach. Clin Breast Cancer. 2009 Feb; 9(1):16-22. View in: PubMed

Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort. BMC Cancer. 2009; 9:43. View in: PubMed

Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol. 2008 Dec 1; 26(34):5544-52. View in: PubMed

HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res. 2008 Dec 1; 14(23):7861-70. View in: PubMed

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008 Dec; 112(3):533-43. View in: PubMed

Breast cancer risk and hormone receptor status in older women by parity, age of first birth, and breastfeeding: a case-control study. Cancer Epidemiol Biomarkers Prev. 2008 Jul; 17(7):1723-30. View in: PubMed

Mitochondrial DNA G10398A variant is not associated with breast cancer in African-American women. Cancer Genet Cytogenet. 2008 Feb; 181(1):16-9. View in: PubMed

Timing of menarche and first full-term birth in relation to breast cancer risk. Am J Epidemiol. 2008 Jan 15; 167(2):230-9. View in: PubMed

The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer. Breast Cancer Res. 2008; 10(4):R58. View in: PubMed

A variant in the cytochrome p450 oxidoreductase gene is associated with breast cancer risk in African Americans. Cancer Res. 2007 Apr 15; 67(8):3565-8. View in: PubMed

Serum organochlorines and breast cancer: a case-control study among African-American women. Cancer Causes Control. 2007 Feb; 18(1):29-39. View in: PubMed

EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs. 2007; 67(14):2045-75. View in: PubMed

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007; 131(1):18-43. View in: PubMed

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007 Jan 1; 25(1):118-45. View in: PubMed

Oral contraceptive use and risk of breast carcinoma in situ (United States). Cancer Causes Control. 2006 Nov; 17(9):1155-62. View in: PubMed

How is Her-2/neu status established when Her-2/neu and chromosome 17 centromere are both amplified? Am J Clin Pathol. How is Her-2/neu status established when Her-2/neu and chromosome 17 centromere are both amplified? Am J Clin Pathol. 2006 Nov; 126(5):673-4. View in: PubMed

Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol. 2006 Jul; 169(1):279-93. View in: PubMed

HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw. 2006 Jul; 4 Suppl 3:S1-22; quiz S23-4. View in: PubMed

Breast cancer risk estimates for relatives of white and African American women with breast cancer in the Women's Contraceptive and Reproductive Experiences Study. J Clin Oncol. 2006 Jun 1; 24(16):2498-504. View in: PubMed

Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 2006 May; 15(5):946-54. View in: PubMed

Lifetime recreational exercise activity and breast cancer risk among black women and white women. J Natl Cancer Inst. 2005 Nov 16; 97(22):1671-9. View in: PubMed

Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res. 2005 Sep 15; 11(18):6598-607. View in: PubMed

Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat. 2005 Sep; 93(1):3-11. View in: PubMed

Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 2005 Aug; 6(3):240-6. View in: PubMed

Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res. 2005 Jul 1; 65(13):5907-16. View in: PubMed

Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol. 2005 Apr 10; 23(11):2534-43. View in: PubMed

Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'. Breast Cancer Res Treat. 2005 Mar; 90(1):1-3. View in: PubMed

Racial differences in the familial aggregation of breast cancer and other female cancers. Breast Cancer Res Treat. 2005 Feb; 89(3):227-35. View in: PubMed

Body weight correlates with mortality in early-stage breast cancer. Arch Surg. 2004 Sep; 139(9):954-58; discussion 958-60. View in: PubMed

Impact of reproductive factors and lactation on breast carcinoma in situ risk. Int J Cancer. 2004 May 20; 110(1):102-9. View in: PubMed

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst. 2004 May 19; 96(10):759-69. View in: PubMed

Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng Des Sel. 2004 Apr; 17(4):315-23. View in: PubMed

Identification of TP53 mutations in human cancers using oligonucleotide microarrays. Methods Mol Med. 2004; 97:323-35. View in: PubMed

Lifetime recreational exercise activity and risk of breast carcinoma in situ. Cancer. 2003 Nov 15; 98(10):2161-9. View in: PubMed

Antibody-mediated targeting of replication-competent retroviral vectors. Hum Gene Ther. 2003 May 20; 14(8):789-802. View in: PubMed

Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial. J Clin Oncol. 2003 Mar 1; 21(5):864-70. View in: PubMed

P7 antigen expression in human breast cancer. Clin Cancer Res. 2003 Jan; 9(1):201-6. View in: PubMed

Comparison of different antibodies for detection of progesterone receptor in breast cancer. Steroids. 2002 Aug; 67(9):799-813. View in: PubMed

Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol. 2002 Jul 15; 20(14):3095-105. View in: PubMed

The NICHD Women's Contraceptive and Reproductive Experiences Study: methods and operational results. Ann Epidemiol. 2002 May; 12(4):213-21. View in: PubMed

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002 Feb 1; 20(3):719-26. View in: PubMed

Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer. Int J Radiat Oncol Biol Phys. 2002 Feb 1; 52(2):397-405. View in: PubMed

Powered bySC CTSI